Oncoinvent is growing and moving forward with their clinical trials and is now in need of a Quality Assurance Officer with particular interest in quality systems and regulated electronic systems.
The QA Officer will support Oncoinvent’s organization in being compliant to applicable regulations and guidelines, such as Good Manufacturing Practice, Good Laboratory Practice, Good Distribution Practice and Good Clinical Practice by working closely with colleagues from the different departments.
As a company in a highly regulated industry, there is also need for a person who is interested in working with computerised systems, both hands on as support to the organisation and from a high-level view, ensuring that systems are kept in their validated state.
Oncoinvent will ensure that the right candidate will receive the training and guidance required to perform the tasks of the position.
The company prides itself with an inclusive working environment with a shared vision, in new modern facilities in Nydalen in Oslo, close to the sub way station.
The holder of this position should have the following documented qualifications and experience:
We are furthermore looking for a candidate with an interest and/or experience in:
The holder of this position will be based at Oncoinvent AS, Gullhaugveien 7, 0484 Oslo. The position will report to the Head of QA.
Please submit your application with a motivational letter stating “why Oncoinvent” and what you can contribute to the position as well as an updated CV. Application without this will not be reviewed further.
Oncoinvent is a privately held Norwegian company based in Nydalen, Oslo. The company is committed to developing novel, innovative products to provide better treatment options for cancer patients.
The Oncoinvent team consists of 39 employees and the company anticipates further growth.
In December 2017 Oncoinvent finished building a state-of-the-art manufacturing facility to produce drug product intended for use in pre-clinical and clinical trials. Clinical trials for Oncoinvent’s lead product, Radspherin®, started in 2020. For further details on Oncoinvent see www.oncoinvent.com.
The facility received a GMP certificate from the Norwegian Medical Agency in February of 2019. The approval provides the company with the necessary flexibility and capacity for manufacturing clinical trial material for both patients and trial sites, as well as developing the company further.
The company’s lead product candidate Radspherin® is a novel alpha-emitting radioactive microsphere suspension designed for treatment of micro-metastatic cancers in body cavities. The radium-224 based therapeutic, Radspherin® has shown strong and consistent anticancer activity at doses being essentially non-toxic in preclinical studies. It is anticipated that the product can potentially treat several forms of micro-metastatic cancer.
+47 464 40 045
Jan A. Alfheim is a business executive with over thirty years’ experience bringing product ideas and technology to the chemical and pharmaceutical markets, from product concept inception through discovery and development phases to final marketing campaign and launch.
With experience in research, project management, business development & partnering, company start-ups, and product launches, Alfheim comes from Nordic Nanovector ASA where he was Chief Executive Officer from 2011 until 2014 and Chief Operating Officer from 2014 to 2016. Prior to working at Nordic Nanovector, he has held various senior roles including Chief Business Officer at Clavis Pharma, President of StemPath Inc, Director of Business Development at Neurochem Inc and Project Director at Nycomed Imaging. Mr. Alfheim holds a MSc from Concordia University and a MBA from McGill University.